Quantum Medical Update is a CME initiative produced by the in-house clinical team of Quantum Diagnostics. This monthly newsletter is in-line with our commitment to better service our doctors.
Test Offering, not Additional Information, May Increase HIV Testing Uptake in...Humphrey Misiri
Abstract
Objectives:To evaluate patient HIV knowledge and testing experience and assess the effect of an HIV
informational handout on HIV testing propensity.
Design:Cross sectional, descriptive techniques were employed to assess demographics, HIV knowledge and
HIV testing experience. A randomized controlled trial was performed to determine if an HIV/AIDS
information sheet influenced testing propensity.
Setting:Blantyre Adventist Hospital Outpatient Clinic.
Subjects:Non-emergency patients over 18 years old attending during consulting hours.
Interventions:All subjects answered a questionnaire. For the randomized controlled trial component, half
received an HIV information handout.
Main Outcome Measures:Proportions were calculated to evaluate testing experience. Logistic regression
was used to assess impact of written information and demographics on HIV testing propensity.
Results:490 participants were recruited, of whom 57% had never been tested for HIV. O f the untested, 88%
had never been offered an HIV test. O f those that had never been offered a test, 46% desired one. The sample
was highly knowledgeable about HIV. Reading an information sheet had no impact on HIV knowledge
(p=0.736 to 0.788) or desire for testing (p=0.387). However, age (OR=0.97,95% CI (0.95,0.99)) and gender
(OR=1.85, 95%CI (1.06, 3.23)) significantly correlated with testing propensity.
Conclusions:A large percentage of patients who have never been offered HIV testing desire testing. More
frequent HIV test offering by clinicians fcould improve testing rates. Clinician education programmes should
be developed to increase test offering. Furthermore, written health information in a setting of high HIV/AIDS
knowledge may not change behaviour. Alternative methods should be employed to encourage HIV testing
uptake.
Quantum Medical Update is a CME initiative produced by the in-house clinical team of Quantum Diagnostics. This monthly newsletter is in-line with our commitment to better service our doctors.
Test Offering, not Additional Information, May Increase HIV Testing Uptake in...Humphrey Misiri
Abstract
Objectives:To evaluate patient HIV knowledge and testing experience and assess the effect of an HIV
informational handout on HIV testing propensity.
Design:Cross sectional, descriptive techniques were employed to assess demographics, HIV knowledge and
HIV testing experience. A randomized controlled trial was performed to determine if an HIV/AIDS
information sheet influenced testing propensity.
Setting:Blantyre Adventist Hospital Outpatient Clinic.
Subjects:Non-emergency patients over 18 years old attending during consulting hours.
Interventions:All subjects answered a questionnaire. For the randomized controlled trial component, half
received an HIV information handout.
Main Outcome Measures:Proportions were calculated to evaluate testing experience. Logistic regression
was used to assess impact of written information and demographics on HIV testing propensity.
Results:490 participants were recruited, of whom 57% had never been tested for HIV. O f the untested, 88%
had never been offered an HIV test. O f those that had never been offered a test, 46% desired one. The sample
was highly knowledgeable about HIV. Reading an information sheet had no impact on HIV knowledge
(p=0.736 to 0.788) or desire for testing (p=0.387). However, age (OR=0.97,95% CI (0.95,0.99)) and gender
(OR=1.85, 95%CI (1.06, 3.23)) significantly correlated with testing propensity.
Conclusions:A large percentage of patients who have never been offered HIV testing desire testing. More
frequent HIV test offering by clinicians fcould improve testing rates. Clinician education programmes should
be developed to increase test offering. Furthermore, written health information in a setting of high HIV/AIDS
knowledge may not change behaviour. Alternative methods should be employed to encourage HIV testing
uptake.
Mills-Peninsula Health Services 2013 Cancer Symposium presentation - Brad Ekstrand, MD/PhD, California Cancer Care Mills-Peninsula Health Services San Mateo, CA
The utility-visual-inspection-with-acetic-acid-cervical-cancer-screening-ecoa...Amarlasreeja
Cervical cancer is potentially preventable but still remains a leading cause of cancer mortality in in developing countries like Nigeria. Cytology-based screening programmers are difficult to maintain in these countries.
Screening for Prostate cancer has had many different opinions and much research has been conducted in the last 20 years. In this presentation we will discuss the current guidelines for proper screening and gain more insight into men’s health.
Presentation by Prof. George Gray, Director of the Centre for Risk Science and Public Health, George Washington University, at the Workshop on Risk Assessment in Regulatory Policy Analysis (RIA), Session 9, Mexico, 9-11 June 2014. Further information is available at http://www.oecd.org/gov/regulatory-policy/
Trevor Hawkins, M.D., M.P.H. of the Univeristy of New Mexico and Southwest CARE Center, presents "Top Ten HIV Clinical Controversies 2014" at AIDS Clinical Rounds
Max Niggl from People Living With HIV/AIDS Victoria discusses gay men's lack of knowledge of HPV and anal cancer, and the need for screening and education. This presentation was given at the AFAO HIV Educators' Conference 2008.
This is a file which is meant to help students in preparing slides for seminar presentation as well as revision for tutorial. it does not cover all about chlamydial trachomatis.
Mills-Peninsula Health Services 2013 Cancer Symposium presentation - Brad Ekstrand, MD/PhD, California Cancer Care Mills-Peninsula Health Services San Mateo, CA
The utility-visual-inspection-with-acetic-acid-cervical-cancer-screening-ecoa...Amarlasreeja
Cervical cancer is potentially preventable but still remains a leading cause of cancer mortality in in developing countries like Nigeria. Cytology-based screening programmers are difficult to maintain in these countries.
Screening for Prostate cancer has had many different opinions and much research has been conducted in the last 20 years. In this presentation we will discuss the current guidelines for proper screening and gain more insight into men’s health.
Presentation by Prof. George Gray, Director of the Centre for Risk Science and Public Health, George Washington University, at the Workshop on Risk Assessment in Regulatory Policy Analysis (RIA), Session 9, Mexico, 9-11 June 2014. Further information is available at http://www.oecd.org/gov/regulatory-policy/
Trevor Hawkins, M.D., M.P.H. of the Univeristy of New Mexico and Southwest CARE Center, presents "Top Ten HIV Clinical Controversies 2014" at AIDS Clinical Rounds
Max Niggl from People Living With HIV/AIDS Victoria discusses gay men's lack of knowledge of HPV and anal cancer, and the need for screening and education. This presentation was given at the AFAO HIV Educators' Conference 2008.
This is a file which is meant to help students in preparing slides for seminar presentation as well as revision for tutorial. it does not cover all about chlamydial trachomatis.
The Papanicolaou test (also called Pap smear, Pap test, cervical smear, or smear test) is a screening test used in gynecology to detect premalignant and malignant (cancerous) processes in the ectocervix. http://docturs.com/dd/pg/groups/2392/cervical-smear-test-pap-test/
Review from the 24th Conference on Retroviruses and Opportunistic Infections (CROI) – 2017
Charles Hicks, M.D.
April 21st, 2017
UCSD HIV & Global Health Rounds
HPV infection and anal dysplasia in Vancouver: findings from the ManCount Survey.CBRC
HPV infection and anal dysplasia in Vancouver: findings from the ManCount Survey. Presented by Mark Gilbert, BC CDC, at the 5th Annual Gay Men's Health Summit held in Vancouver, BC on November 9th and 10th, 2009.
Cervical Cancer Care Seeking Behaviour Among Community Women, Jos-North, Plat...AI Publications
Most people are infected with HPV shortly after the onset of sexual activity. The screening rate has not reached the WHO's target. This study seeks to assess community women's care-seeking behavior toward cervical cancer screening participation. A cross-sectional design was employed, community women who met the criteria for inclusion were given a self-developed questionnaire conveniently. Results show that the majority (51.9%) of women were between the ages of 21-29, majority (83.0%) had only one sexual partner, majority (75.0%) were extremely poor with very low yearly income of less than 284,700.00 Naira, and 19.3% experienced gynecological symptoms. Majority (78.5%) have the fear of being diagnosed with cancer, and 69.6% fear exposing their genital area. Women agreed that HPV is the causative organism of cervical cancer and husband do not allow someone to touch their wives’ private parts. They moderately agreed that a woman must obtain consent from her husband before going for screening, that exposing their private part is culturally inappropriate. Only 14.1% of those surveyed had ever undergone a cervical cancer screening. Among the respondents who had screened, 57.9% had bad experience. There is a significant difference between age group and screening where majority who had screened were older women within the age group 30-65 years (X2=8.402; P-value=0.005) and having gynecological symptoms has positive influence on screening participation (X2=7.422; P-value=0.012). The majority (92.6%) believed that husband involvement and the caregiver's friendly attitude are among other facilitating conditions to screening. In conclusion, there was low screening participation among community women. Women's knowledge of cervical cancer and screening did not translate into participating in screening. Low socioeconomic status has a significant impact on screening, screening rates were higher among older women than younger ones, and experiencing gynecological symptoms has a positive impact on screening. It was therefore recommended that interventions aimed at enhancing care seeking behavior based on women's needs be implemented.
An overview of the design, process, results and recommendations of the recent sero conversion study by the National Centre in HIV Epidemiology and Clinical Research, the Australian Research Centre in Sex, Health and Society, and the National Centre in HIV Social Research.
This presentation was given at the AFAO HIV Educators Conference in May 2008.
HPV infection, cervical abnormalities, and cancer in HIV-infected women in Mu...Dr.Samsuddin Khan
Background: HIV-infected women are at a higher risk of cervical intraepithelial neoplasia (CIN) and cancer than women in the general population, partly due to a high prevalence of persistent human papillomavirus (HPV) infection. The aim of the study was to assess the burden of HPV infection, cervical abnormalities, and cervical cancer among a cohort of HIV-infected women as part of a routine screening in an urban overpopulated slum setting in Mumbai, India.
Methods: From May 2010 to October 2010, Médecins Sans Frontières and Tata Memorial Hospital Mumbai offered routine annual Pap smears and HPV DNA testing of women attending an antiretroviral therapy (ART) clinic and a 12-month follow-up. Women with abnormal test results were offered cervical biopsy and treatment, including treatment for sexually transmitted infections (STIs).
Results: Ninety-five women were screened. Median age was 38 years (IQR: 33–41); median nadir CD4-count 143 cells/µL (IQR: 79–270); and median time on ART 23 months (IQR:10–41). HPV DNA was detected in 30/94 women (32%), and 18/94 (19%) showed either low-grade or high-grade squamous intraepithelial lesions (LSIL/HSIL) on Pap smear. Overall, >50% had cervical inflammatory reactions including STIs. Of the 43 women with a cervical biopsy, eight (8.4%) had CIN-1, five (5.3%) CIN-2, and two (2.1%) carcinoma in situ. All but one had HPV DNA detected (risk ratio: 11, 95% confidence interval: 3.3–34). By October 2011, 56 women had completed the 12-month follow-up and had been rescreened. No new cases of HPV infection/LSIL/HSIL were detected.
Conclusion: The high prevalence of HPV infection, STIs, and cervical lesions among women attending an ART clinic demonstrates a need for routine screening. Simple, one-stop screening strategies are needed. The optimal screening interval, especially when resources are limited, needs to be determined.
Clinical Impact of New HIV Data From CROI 2019hivlifeinfo
March 4-7, 2019; Seattle, Washington
In this downloadable slideset, expert faculty members summarize key studies from this important annual conference.
Format: Microsoft PowerPoint (.ppt)
File Size: 576 KB
Released: March 22, 2019
Presented by Carol Roye, EdD, CPNP, RN, Professor of Nursing, Assistant Dean for Research, Hunter College School of Nursing at the 2013 National Chlamydia Coalition Meeting
A brief update on the National Chlamydia Coalition by Ashley Coffield, MPA, Senior Fellow, Partnership for Prevention. Presented at the 2012 National Chlamydia Coalition meeting.
Presented by Michael Horberg, MD, MAS, FACP, FIDSA,
Executive Director Research, Mid-Atlantic Permanente Medical Group, Director, HIV/AIDS Kaiser Permanente, at the 2012 National Chlamydia Coalition meeting.
Presented by Richard Crosby, PhD, DDI Endowed Professor and Chair, Department of Health Behavior, University of Kentucky at the 2012 National Chlamydia Coalition meeting.
Presented by Marc Garufi, Chief, Public Health Branch, Office of Management and Budget (OMB), Executive Office of the President at the 2012 National Chlamydia Coalition meeting.
Presented by Jo Valentine, MSW, Associate Director, Office of Health Equity, Division of STD Prevention, CDC, at the 2012 National Chlamydia Coalition meeting
A brief update on the National Chlamydia Coalition by Ashley Coffield, MPA, Senior Fellow, Partnership for Prevention. Presented at the 2012 National Chlamydia Coalition meeting.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Acute scrotum is a general term referring to an emergency condition affecting the contents or the wall of the scrotum.
There are a number of conditions that present acutely, predominantly with pain and/or swelling
A careful and detailed history and examination, and in some cases, investigations allow differentiation between these diagnoses. A prompt diagnosis is essential as the patient may require urgent surgical intervention
Testicular torsion refers to twisting of the spermatic cord, causing ischaemia of the testicle.
Testicular torsion results from inadequate fixation of the testis to the tunica vaginalis producing ischemia from reduced arterial inflow and venous outflow obstruction.
The prevalence of testicular torsion in adult patients hospitalized with acute scrotal pain is approximately 25 to 50 percent
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Charlotte Gaydos: Using Self-Collected Specimens to Improve and Extend Delivery of Chlamydia Screening
1. Using Self-Collected Specimens to Improve and Extend Delivery of Chlamydia Screening: A Roundtable Discussion Charlotte A. Gaydos, MS, DrPH Professor Division of Infectious Diseases Johns Hopkins University National Chlamydia Coalition Washington, DC December 3-4, 2009
8. Relative Comparison of Sensitivity of Various Types of Tests for Detection of Chlamydia or Gonorrhea *Nucleic Acid Amplification Test NAAT* Signal Amplification Test Direct Probe Test Enzyme Immunoassay Sensitivity Range/Sample 1 10 10 2 10 3 10 4 10 5 10 6 10 7 10 8 Number/ organisms per sample
12. 16.0% 5.4% 7.9% 10.4% 4.1% Female U.S. Army Recruits: RESULTS 7.9% Gaydos et al. STD 30:539-544, 2003 Mean Age: 20.6 years. OR 2.8 (proportion <25 yr = 85.8%) 1996: 8.51% 1997: 9.68% 1998: 9.90% 1999: 9.92% p = 0.018, using 1996 as referent
13. South: n = 10,963 (12.3%) Northeast: n = 3,746 (7.5%) Midwest: n = 4,128 (7.3%) West: n = 3,779 (5.8%) Territories: n =391 (9.5.%) Female U.S. Army Recruits: 1996-1999 Chlamydia Prevalence, by urine LCR (n=23,007) CDC Reporting Region: Northeast, South, Midwest, West, Territories 3 individuals missing region assignment.
14. Chlamydia or Gonorrhea (13.6%) ED Mehta SD et al. Sex Transm Dis 2001;28:33 22% >1 sex partner in the past 90 days; 37% male, vol rate 77%; 28% new sex partner in the past 90 days; 76% of infections were undetected by clinicians at initial ED visit
15. Vaginal Swabs Are Appropriate Specimens for Diagnosis of Genital Tract Infection with C. trachomatis Schachter et al. JCM 2003;41:3784-3789 NAAT sensitivity: Vaginal Swabs 93% Cervical Swabs 91% FVU 80.6% Culture Sensitivity 83.5% Specificities All Specimens >99% GenProbe APTIMA COMBO2 now FDA cleared for vaginal swabs
16.
17. Assessment of ease of use of vaginal swabs Most Women reported that vaginal swabs were “easy” to collect!
31. Female CT Prevalence: Results by Age (N = 1191*) 11.1% Infected 6.8% Infected 15.3% Infected *12 did not report age. There were 9 women 14 yr old, all were chlamydia negative 1.2% Infected
32.
33.
34.
35.
36.
37.
38.
39. Male Questionnaire Results Home collection (N = 501) Swab 89.8% 94.0% 91.4% Urine 95.3% No swab: 8; No urine 2